Delving into the Latest Updates on LX-22001 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

H+/K+ ATPase

Mechanism

P-CAB(Potassium-competitive acid blockers)

Therapeutic Areas

Digestive System Disorders

Active Indication

Duodenal UlcerEsophagitis, PepticPeptic Ulcer Hemorrhage

Inactive Indication-

Originator Organization

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Active Organization

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价注射用LX22001单次和多次给药后在中国健康受试者中的安全性和耐受性；次要目的：评价注射用LX22001单次和多次给药后的药代动力学（PK）和药效动力学（PD）特征；评价注射用LX22001与替戈拉生片单次给药后的生物利用度。

[Translation]

The primary objective is to evaluate the safety and tolerability of LX22001 for injection after single and multiple administrations in healthy Chinese subjects. The secondary objectives are to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of LX22001 for injection after single and multiple administrations; and to evaluate the bioavailability of LX22001 for injection and tegrasin tablets after single administration.

Start Date31 Jul 2024

Sponsor / Collaborator

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

[+1]

100 Clinical Results associated with LX-22001

Login to view more data

100 Translational Medicine associated with LX-22001

Login to view more data

100 Patents (Medical) associated with LX-22001

Login to view more data

100 Deals associated with LX-22001

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Duodenal Ulcer	Phase 1	CN	Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.	31 Jul 2024
Esophagitis, Peptic	Phase 1	CN	Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.	31 Jul 2024
Peptic Ulcer Hemorrhage	Phase 1	CN	Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.	31 Jul 2024